Healthcare

• The company prioritises expanding regulatory approvals and distribution partnerships across Europe and Asia.

The 18 August result therefore landed near the top of a much lower bar. Underlying net profit fell 22 per cent, or 21 per cent in constant currency. UnderlyingEarnings Per Sharewere A$4.93, against A$6.33. SalesRevenuewas A$2,343.4m, down 1 per cent as reported and up …

The bill seeks to amend the Private Health Insurance Act 2007 so that eligible policyholders aged 65 and over receive the same income-tested rebate percentage as those under 65. It also includes a related technical amendment to the Age Discrimination Act 2004. Parliamentary material …

CSL Limited (ASX:CSL) reported total operating revenue of US$15,797 million for FY2026. CSL Behring accounted for US$11,387 million, CSL Vifor for US$2,379 million and CSL Seqirus for US$2,031 million. The segments cover different product markets, including immunoglobulins and other plasma-based medicines, influenza vaccines, and …

The Phase I/IIa SECuRE study is evaluating the safety and efficacy of copper-67 SAR-bisPSMA in metastatic castration-resistant prostate cancer (mCRPC). Clarity Pharmaceuticals (ASX:CU6) confirmed that 16 participants had enrolled in the cohort expansion main group, where they are being assessed for up to six …

For the financial year ended 30 June 2026, Clinuvel Pharmaceuticals Limited (ASX:CUV) reported revenues of A$94.0m and profit before tax of A$47.7m. The company also disclosed cash reserves of A$252.1m, identified in itsAnnual Reportas a non-IFRS measure, andReturn on Equityof 13%. These figures describe …

The ACTION3 study evaluates DMX-200, also known as reprotinib, in people with FSGS, a condition involving kidney scarring that can impair kidney function. DMX-200 is being developed as an oral inhibitor of the chemokine receptor CCR2. Trial outcomes will determine whether the investigational treatment …